Abstract

Progress in tackling technical challenges in the development of bispecific antibodies and emerging opportunities in the red-hot immuno-oncology space have catalyzed a flurry of dealmaking activity for bispecific platform companies. Progress in tackling technical challenges in the development of bispecific antibodies and emerging opportunities in the red-hot immuno-oncology space have catalyzed a flurry of dealmaking activity for bispecific platform companies.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call